MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Veradermics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$122.28+13.46 (+12.37%)
Close on Oct 19, 2026
- Market cap
- $4.94B
- P/E (TTM)
- –
- Dividend yield
- –
Veradermics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Veradermics | Industry median |
|---|---|---|
| Market Cap | $5.11B | $197.05M |
| Enterprise Value | $4.29B | $106.56M |
| PB Ratio | 6.28 | 2.14 |
| P/TBV Ratio | 6.28 | 2.46 |
Income (trailing twelve months)
| Measure | Veradermics | Industry median |
|---|---|---|
| Operating Income | -$72.35M | -$21.44M |
| Pretax Income | -$70.00M | -$14.45M |
| Net Income | -$70.00M | -$22.46M |
| EBITDA | -$72.35M | -$16.91M |
| EPS (Diluted) | -$111.91 | -$0.83 |
Returns
| Measure | Veradermics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -19.0% | -53.1% |
| Return on Assets (ROA) | -8.48% | -41.0% |
| Return on Capital Employed (ROCE) | -8.89% | -37.8% |
Balance sheet
| Measure | Veradermics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $819.90M | $62.42M |
| Net Cash (Debt) | $819.90M | $15.68M |
| Net Cash Per Share | $19.62 | $0.65 |
| Equity (Book Value) | $813.61M | $48.79M |
| Book Value Per Share | $19.47 | $1.36 |
| Tangible Book Value | $813.61M | $23.06M |
| Working Capital | $813.05M | $75.77M |
Financial position
| Measure | Veradermics | Industry median |
|---|---|---|
| Current Ratio | 70.53 | 3.30 |
| Quick Ratio | 70.11 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Veradermics | Industry median |
|---|---|---|
| Operating Cash Flow | -$71.60M | -$12.35M |
| Capital Expenditures | -$24.00K | -$1.06M |
| Free Cash Flow | -$71.63M | -$20.28M |
| FCF Per Share | -$1.71 | -$0.41 |
Efficiency
| Measure | Veradermics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.33M | -$732.08K |
| Employee Count | 21 | 73 |
Dividends and yields
| Measure | Veradermics | Industry median |
|---|---|---|
| Earnings Yield | -1.37% | -21.2% |
| FCF Yield | -1.40% | -7.64% |
Shares
| Measure | Veradermics | Industry median |
|---|---|---|
| Shares Outstanding | 41,780,100 | 59,128,900 |
| Shares Change (YoY) | 1.09% | 11.1% |
| Shares Change (QoQ) | 11.9% | 0.54% |
| Float | 25,729,300 | 48,744,500 |
| Shares Held by Insiders | 38.4% | 11.8% |
| Shares Held by Institutions | 81.6% | 59.4% |
Taxes
| Measure | Veradermics | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Veradermics | Industry median |
|---|---|---|
| Altman Z-Score | 253.47 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Veradermics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.